Errata ISI SCOPUS
ESMO Open  (2021)

First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update (vol 6, 100273, 2021)

Reck M.; Ciuleanu T.E.; Cobo M.; Schenker M.; Zurawski B.; Menezes J.; Richardet E.; Bennouna J.; Felip E.; Juan-Vidal O.; Alexandru A.; Sakai H.; Lingua A.; Reyes F.; Souquet P.J.; et. al.

Abstract

The authors regret that at the time the article was published there were some minor errors which have now been corrected. In Figure 4 (Grade 3/4 TRAE onset by treatment cycle), the numbers of patients at risk in the chemotherapy arm between cycles 21-22 and 31-32 were corrected as per the below. In Supplementary Figure S12 (Grade 1/2 TRAE onset by treatment cycle), the numbers of patients at risk in the chemotherapy arm between cycles 21-22 and 31-32 were corrected and a revised Supplementary Data file provided. The authors would like to apologize for any inconvenience caused.

Más información

Título según WOS: First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update (vol 6, 100273, 2021)
Título según SCOPUS: Corrigendum to ‘First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update’: [ESMO Open Volume 6, Issue 5, October 2021, 100273] (ESMO Open (2021) 6(5), (S2059702921002350), (10.1016/j.esmoop.2021.100273))
Título de la Revista: ESMO Open
Volumen: 6
Número: 6
Editorial: Elsevier B.V.
Fecha de publicación: 2021
Idioma: English
DOI:

10.1016/j.esmoop.2021.100345
Notas: ISI, SCOPUS